Overview

Pharmacodynamics and Safety of CDFR0209

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, two-way crossover study to investigate the pharmacodynamics(24 hour gastric pH) and the safety between repeated doses of CDFR0209 and Losec in Healthy Male Volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Ajou University School of Medicine

Collaborator:

CTC Bio, Inc.

Treatments:

Omeprazole